person

Paweł L.

Country
Poland
Department
NZOZ Vitamed

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 42 partner sites.

Specializations

Inflammatory Bowel Disease

The investigator concentrates on therapeutic strategies for ulcerative colitis, addressing disease activity and mucosal healing.

  • Induction and maintenance therapies
  • Biologic biosimilarity assessments
  • Combination regimens with immunomodulators

Efforts support expanding treatment options for patients with chronic intestinal inflammation.

Respiratory and Interstitial Lung Diseases

Research activities focus on novel interventions for chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis, including progressive fibrosing phenotypes.

  • Anti‑inflammatory inhaled agents
  • Antifibrotic oral and inhaled compounds
  • Targeted therapies for pulmonary sarcoidosis

These studies aim to improve lung function and reduce exacerbation frequency.

Neurological Disorders

The clinical portfolio includes trials targeting neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

  • Disease‑modifying antibodies
  • Neuroprotective small molecules
  • Biomarker‑guided early‑stage interventions

Objectives center on slowing progression and preserving neurological function.

Dermatological Conditions

Investigations address skin disorders, notably acne vulgaris, atopic dermatitis, and plaque psoriasis, evaluating topical and systemic agents.

  • Long‑term safety of novel topicals
  • Systemic immunomodulators for severe disease
  • Quality‑of‑life impact assessments

Therapeutic goals include reducing lesion severity and enhancing patient well‑being.

Migraine and Headache Disorders

The investigator explores preventive and acute treatments for migraine, with emphasis on chronic and episodic subtypes.

  • Oral CGRP antagonists
  • Comparative efficacy versus established agents
  • Patient‑reported outcome measures

Studies aim to decrease attack frequency and improve daily functioning.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.